Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
43
NVO Quote, Financials, Valuation and Earnings
Last price:
$56.24
Seasonality move
:
3.8%
Day range:
$53.36 - $55.42
52-week range:
$43.08 - $93.80
Dividend yield:
3.13%
P/E ratio:
16.05x
P/S ratio:
5.26x
P/B ratio:
12.08x
Volume:
30M
Avg. volume:
18.8M
1-year change:
-37.12%
Market cap:
$244.9B
Revenue:
$42.1B
EPS (TTM):
$3.43
Analysts' Opinion
-
Consensus RatingNovo Nordisk A/S has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 4 Hold ratings, and 2 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $53.33, Novo Nordisk A/S has an estimated downside of -2.9% from its current price of $55.11.
-
Price Target UpsideAccording to analysts, the highest upside price target is $71.06 representing -100% upside increase from its current price of $55.11.
Fair Value
-
According to the consensus of 11 analysts, Novo Nordisk A/S has -2.9% downside to fair value with a price target of $53.33 per share.
NVO vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk A/S has overperformed the S&P 500 by 4.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novo Nordisk A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk A/S has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Novo Nordisk A/S reported revenues of $11.7B.
Earnings Growth
-
Novo Nordisk A/S earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novo Nordisk A/S reported earnings per share of $0.70.
Enterprise value:
255.7B
EV / Invested capital:
--
Price / LTM sales:
5.26x
EV / EBIT:
12.91x
EV / Revenue:
5.48x
PEG ratio (5yr expected):
1.42x
EV / Free cash flow:
27.66x
Price / Operating cash flow:
26.55x
Enterprise value / EBITDA:
11.10x
Gross Profit (TTM):
$38.3B
Return On Assets:
21.76%
Net Income Margin (TTM):
32.76%
Return On Equity:
68.76%
Return On Invested Capital:
41.85%
Operating Margin:
31.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $30.8B | $39.3B | $46.7B | $10.5B | $11.7B | |
| Gross Profit | $25.9B | $33.3B | $38.3B | $8.8B | $8.9B | |
| Operating Income | $13.3B | $17.3B | $19.8B | $5B | $3.7B | |
| EBITDA | $14.5B | $19.7B | $23B | $5.3B | $4.9B | |
| Diluted EPS | $2.41 | $3.08 | $3.43 | $0.90 | $0.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.2B | $15.7B | $20.2B | $29.2B | $28.6B | |
| Total Assets | $27.1B | $32B | $42.6B | $59.5B | $80.6B | |
| Current Liabilities | $13.8B | $17.2B | $24.5B | $31.2B | $36.9B | |
| Total Liabilities | $16.8B | $21.9B | $29.4B | $41.5B | $53.9B | |
| Total Equity | $10.3B | $10.1B | $13.2B | $18B | $26.7B | |
| Total Debt | $1.9B | $3.2B | $2.8B | $7.7B | $14B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $15.3B | $17.2B | $18.7B | $6.4B | $7.3B | |
| Cash From Investing | -$6.2B | -$7.6B | -$18.8B | -$3.1B | -$2.4B | |
| Cash From Financing | -$8.7B | -$5.6B | -$3.4B | -$2.7B | -$2.8B | |
| Free Cash Flow | $11.1B | $9.8B | $9.2B | $4.6B | $4.8B | |
NVO
Sector
Market Cap
$244.9B
$28.1M
Price % of 52-Week High
58.75%
50.9%
Dividend Yield
3.13%
0%
Shareholder Yield
5.06%
-1.55%
1-Year Price Total Return
-37.13%
-19.36%
Beta (5-Year)
0.665
0.498
Dividend yield:
3.13%
Annualized payout:
$1.45
Payout ratio:
--
Growth streak:
5 years
Technicals
8-day SMA
Buy
Level
$52.21
200-day SMA
Sell
Level
$59.64
Bollinger Bands (100)
Buy
Level
48.6 - 57.06
Chaikin Money Flow
Buy
Level
1.8B
20-day SMA
Buy
Level
$49.95
Relative Strength Index (RSI14)
Buy
Level
67.76
ADX Line
Buy
Level
18.38
Williams %R
Sell
Level
-3.8608
50-day SMA
Buy
Level
$49.27
MACD (12, 26)
Buy
Level
1.02
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
1.7B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.0926)
Buy
CA Score
(Annual)
Level (0.6478)
Buy
Beneish M-Score
(Annual)
Level (-2.5103)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.1185)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Stock Forecast FAQ
In the current month, NVO has received 5 Buy ratings 4 Hold ratings, and 2 Sell ratings. The NVO average analyst price target in the past 3 months is $53.33.
-
Where Will Novo Nordisk A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk A/S share price will drop to $53.33 per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk A/S?
Analysts are divided on their view about Novo Nordisk A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk A/S is a Sell and believe this share price will rise from its current level to $42.00.
-
What Is Novo Nordisk A/S's Price Target?
The price target for Novo Nordisk A/S over the next 1-year time period is forecast to be $53.33 according to 11 Wall Street analysts, 5 of them rate the stock a Buy, 2 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is NVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk A/S is a Buy. 5 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVO?
You can purchase shares of Novo Nordisk A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk A/S shares.
-
What Is The Novo Nordisk A/S Share Price Today?
Novo Nordisk A/S was last trading at $56.24 per share. This represents the most recent stock quote for Novo Nordisk A/S. Yesterday, Novo Nordisk A/S closed at $55.11 per share.
-
How To Buy Novo Nordisk A/S Stock Online?
In order to purchase Novo Nordisk A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NVO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVO
Sector
P/E ratio
16.05x
24.09x
PEG ratio
1.42x
-0.01x
P/B ratio
12.08x
1.83x
Price / LTM sales
5.26x
1.59x
Growth Metrics
NVO
Sector
Revenue growth
11.8%
4.68%
Earnings growth
-21.84%
10.88%
Revenue (5-year growth)
18.15%
6.45%
Earnings forecast
$0.92
-$0.18
Profitability
NVO
Sector
Profitability FY 2024
$35.3B
$3.6M
Return on invested capital
41.85%
-31.87%
Return on assets
21.76%
-28.18%
Return on equity
68.76%
-37.89%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Feb
4
Balance Sheet
NVO
Sector
Total cash
$5.1B
$26.2M
Short term investments
$1.5B
$25.7M
Total assets
$64.7B
$76.7M
Long term debt
$14B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
